Beacon Biosignals

Beacon Biosignals is a Boston-based neurotechnology company that applies advanced machine learning to electroencephalography (EEG) data, enabling the scalable measurement of neural biomarkers for clinical and pharmaceutical applications. The company's flagship product, the Dreem headband, is a consumer-grade wearable EEG device that captures high-quality brain activity data in real-world, at-home settings, removing the traditional reliance on costly and logistically complex in-clinic recordings. This hardware is paired with a sophisticated cloud analytics platform that processes and interprets raw EEG signals, transforming them into actionable, reproducible biomarkers suited for use as clinical trial endpoints. Together, these components form an end-to-end solution that bridges the gap between neuroscience research and scalable drug development infrastructure.

Beacon Biosignals has established a meaningful position in the neurodiagnostics space, having raised $45 million in Series B funding to support the expansion of its platform and commercial partnerships. The company has built credibility with major pharmaceutical organizations seeking objective, quantifiable brain-based endpoints to support trials in CNS disorders such as epilepsy, sleep disorders, Alzheimer's disease, and schizophrenia. By enabling decentralized data collection through its wearable hardware, Beacon has helped sponsors increase patient enrollment reach while reducing operational burden in studies that traditionally required overnight polysomnography or supervised EEG monitoring. Their growing portfolio of validated biomarkers represents a meaningful step toward making neural measurement a routine component of drug development workflows.

Beacon Biosignals matters to the broader neurotech industry because it addresses one of the field's most persistent challenges: the difficulty of measuring brain function reliably, remotely, and at scale. The lack of validated, objective neural endpoints has long been a bottleneck in CNS drug development, contributing to high failure rates and costly trial designs. By combining wearable EEG technology with machine learning-driven analytics, Beacon is helping to standardize how the industry captures and interprets brain activity data across large, geographically distributed patient populations. Their work accelerates the path toward more precise neurological diagnostics and opens the door to a future where continuous brain monitoring can inform both drug discovery and clinical care in ways that were previously impractical.